Effect of Insect-derived Protein Supplements on Protein Synthesis and mTORC1 Activation

NCT05457218 | Completed

• 1 other identifier: 220601
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine the ability of insect-derived protein supplements (IPC80 and Whole Buffalo Powder Ynsect®) to activate the mTORC1 pathway and protein synthesis in muscle cells. To achieve this aim, participants will consume a supplemental dose (0.25 g/kg body weight) of IPC80,Whole Buffalo Powder or whey protein. Blood samples will be drawn before and 15, 30, 60 and 90 minutes after the supplementation. Protein synthesis will be assessed using stably transfected C2C12 muscle cells with a plasmid (pcDNA3 luciferase) and to determine the ability of a protein source to activate mTORC1, stably transfected C2C12 muscle cells with a plasmid (pcDNA3-TOP luciferase) where the luciferase mRNA contains a 5'TOP. 5'TOP which is specifically regulated by mTORC1 activity will be used.

Conditions

Effect of Food Supplement

Keywords

Protein synthesis; Protein supplement; mTORC1 activity; Insect-derived protein

Outcome Measures

Primary Outcomes (4)

• Muscle protein synthesis

  To measure muscle protein synthesis, stably transfected C2C12 muscle cells with a plasmid (pcDNA3 luciferase) will be used. C2C12Luc cells will be plated in 24-well plates and differentiated over 4 days. Differentiated C2C12 cells will be fasted by washing with PBS and then treating them with Test Media (20% DMEM) for 15 minutes. Fasted muscle cells will then be treated with Test Media containing 0, 2.5, 5, or 10% baseline or fed serum (from blood samples at 15, 30, 60, and 90 minutes after supplementation) for 60 minutes. Cells will be collected in passive lysis buffer and firefly luciferase activity will be determined.

  Baseline (0 hour) to 15 minutes after supplementation

• Muscle protein synthesis

  To measure muscle protein synthesis, stably transfected C2C12 muscle cells with a plasmid (pcDNA3 luciferase) will be used. C2C12Luc cells will be plated in 24-well plates and differentiated over 4 days. Differentiated C2C12 cells will be fasted by washing with PBS and then treating them with Test Media (20% DMEM) for 15 minutes. Fasted muscle cells will then be treated with Test Media containing 0, 2.5, 5, or 10% baseline or fed serum (from blood samples at 15, 30, 60, and 90 minutes after supplementation) for 60 minutes. Cells will be collected in passive lysis buffer and firefly luciferase activity will be determined.

  Baseline (0 hour) to 30 minutes after supplementation

• Muscle protein synthesis

  To measure muscle protein synthesis, stably transfected C2C12 muscle cells with a plasmid (pcDNA3 luciferase) will be used. C2C12Luc cells will be plated in 24-well plates and differentiated over 4 days. Differentiated C2C12 cells will be fasted by washing with PBS and then treating them with Test Media (20% DMEM) for 15 minutes. Fasted muscle cells will then be treated with Test Media containing 0, 2.5, 5, or 10% baseline or fed serum (from blood samples at 15, 30, 60, and 90 minutes after supplementation) for 60 minutes. Cells will be collected in passive lysis buffer and firefly luciferase activity will be determined.

  Baseline (0 hour) to 60 minutes after supplementation

• Muscle protein synthesis

  To measure muscle protein synthesis, stably transfected C2C12 muscle cells with a plasmid (pcDNA3 luciferase) will be used. C2C12Luc cells will be plated in 24-well plates and differentiated over 4 days. Differentiated C2C12 cells will be fasted by washing with PBS and then treating them with Test Media (20% DMEM) for 15 minutes. Fasted muscle cells will then be treated with Test Media containing 0, 2.5, 5, or 10% baseline or fed serum (from blood samples at 15, 30, 60, and 90 minutes after supplementation) for 60 minutes. Cells will be collected in passive lysis buffer and firefly luciferase activity will be determined.

  Baseline (0 hour) to 90 minutes after supplementation

Secondary Outcomes (4)

• mTORC1 activity

  Baseline (0 hour) to 15 minutes after supplementation

• mTORC1 activity

  Baseline (0 hour) to 30 minutes after supplementation

• mTORC1 activity

  Baseline (0 hour) to 60 minutes after supplementation

• mTORC1 activity

  Baseline (0 hour) to 90 minutes after supplementation

Study Arms (3)

Whey protein

EXPERIMENTAL

This arm will be given a supplemental dose of whey protein (0.25 g/kg body weight)

Dietary Supplement: Whey protein

IPC80

EXPERIMENTAL

This arm will be given a supplemental dose of IPC80, an insect-derived protein source (0.25 g/kg body weight)

Dietary Supplement: IPC80

Whole Buffalo Powder

EXPERIMENTAL

This arm will be given a supplemental dose of Whole Buffalo Powder, an insect-derived protein source (0.25 g/kg body weight)

Dietary Supplement: Whole Buffalo Powder

Interventions

Whey protein DIETARY_SUPPLEMENT

The participant will consume a supplemental dose of whey protein (0.25 g/kg body weight)

Whey protein

IPC80 DIETARY_SUPPLEMENT

The participant will consume a supplemental dose of IPC80 (0.25 g/kg body weight)

IPC80

Whole Buffalo Powder DIETARY_SUPPLEMENT

The participant will consume a supplemental dose of Whole Buffalo Powder (0.25 g/kg body weight)

Whole Buffalo Powder

Eligibility Criteria

• Age: 18 Years - 30 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy active male or female
• Normal weight (BMI between 18 and 25 kg/m2)

You may not qualify if:

• Receiving any medication that may interfere with the study.
• Health or dietary restrictions that would be affected by the supplementation protocol.
• Allergy to shellfish (the chitins in the mealworm exoskeleton can activate shellfish allergies)

Sponsors & Collaborators

• University of California, Davis: lead

Study Sites (1)

Hickey Laboratory

Davis, California, 95616, United States

Location

Related Publications (2)

• Philp A, MacKenzie MG, Belew MY, Towler MC, Corstorphine A, Papalamprou A, Hardie DG, Baar K. Glycogen content regulates peroxisome proliferator activated receptor- partial differential (PPAR- partial differential) activity in rat skeletal muscle. PLoS One. 2013 Oct 17;8(10):e77200. doi: 10.1371/journal.pone.0077200. eCollection 2013.

  PMID: 24146969 BACKGROUND

• Jefferies HB, Reinhard C, Kozma SC, Thomas G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4441-5. doi: 10.1073/pnas.91.10.4441.

  PMID: 8183928 BACKGROUND

MeSH Terms

Interventions

Whey Proteins

Intervention Hierarchy (Ancestors)

Milk Proteins; Animal Proteins, Dietary; Dietary Proteins; Proteins; Amino Acids, Peptides, and Proteins; Whey; Milk; Dairy Products; Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages

Study Officials

• Keith Baar, PhD

  UC Davis

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: A randomized double-blind crossover design with neither the subjects nor the investigators knowing who is on which treatment. The interventions will be coded using a blinded alphabetical letter code (A, B, C). A delegate researcher (independent party not further involved in the study) will randomize all interventions using a computer-generated randomization list. The delegate will hand in the code-breaker to the principal investigator in a sealed envelope. The envelope will be stored in a locked filing cabinet in the principal investigator's office, which will also be locked when unoccupied. The envelope will be opened by the principal investigator after completing the analysis of blood samples.
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Participants will consume a supplemental dose (0.25 g/kg body weight) of either IPC80, Whole Buffalo Powder or whey protein. The type of consumed supplementation will be randomized where neither the participant nor investigator will know which supplement is being consumed. Each participant will repeat the protocol three times.

Study Record Dates

• First Submitted: July 6, 2022
• First Posted: July 13, 2022
• Study Start: October 1, 2022
• Primary Completion: June 30, 2023
• Study Completion: September 30, 2024
• Last Updated: October 31, 2024

Record last verified: 2024-10

Locations

US (1)